Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Withanolide E is a natural steroidal lactone isolated from the plant *Physalis peruviana* (Cape gooseberry). It has been identified as a potent sensitizer of various human cancer cell lines, particularly renal cell carcinoma and melanoma, to apoptosis induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and the TLR3 ligand poly(I:C). Its mechanism of action involves the reduction of cellular levels of the antiapoptotic protein c-FLIP (both long and short isoforms) and the enhancement of caspase-8 activation at the death-inducing signaling complex (DISC). Unlike proteasome inhibitors such as bortezomib, withanolide E does not inhibit the proteasome, and its sensitizing effects are dependent on cellular redox changes, as they can be blocked by antioxidants like n-acetyl cysteine. It belongs to the 17-beta-hydroxywithanolide class of compounds and serves as a scaffold for the development of more potent apoptosis-inducing agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on withanolide E.